Type 1 regulatory T cells (Tr1s) are an inducible subtype of regulatory T cells that can play a beneficial (autoimmune diseases, allergy, hematological malignancies) or detrimental role (some solid tumors and infectious diseases) in human diseases. Tr1 cells.
Researchers at Stanford have developed a novel deep-learning-based tool called CytoTRACE2 that interprets single-cell RNA sequencing (scRNA-seq) to enable the discovery of regenerative cells across all tissue types and novel targets in cancer and other diseases.
Researchers at Stanford have found that a vaccine, enhanced with adjuvants that imprint an antiviral state on innate immune cells and non-hematopoietic organ cells, could confer lasting nonspecific protection against diverse pathogens.
Stanford researchers have developed a new technology, Variant-FlowFISH, to enable high-throughput, highly sensitive measurements of how variants, introduced via CRISPR, affect gene expression.
Patients who experience heart attacks often have immediate ischemia and cell death, which causes a decrease in cardiac function, contributing to higher mortality and morbidity.
Researchers at Stanford have created human induced pluripotent stem cells (hiPSCs) derived from adult human dermal fibroblasts exposed to an environmental factor.
SparseGMM, is a new algorithm which is a novel statistical approach for identifying drug targets in cancer patients and other diseases by more accurately modeling biological pathways.
Using their newly developed acetyl-click screening platform, researchers at Stanford have identified riboflavin analogs as small molecule inhibitors of Histone Acetyltransferase 1 (HAT1) with anti-cancer activity.
Stanford researchers in the Mahajan Lab have created a customizable proteomics platform that can identify protein biomarkers to differentiate among ischemic eye diseases and identify novel therapeutic targets to treat them.